These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38367265)

  • 21. Old wine in new bottles: Drug repurposing in oncology.
    Antoszczak M; Markowska A; Markowska J; Huczyński A
    Eur J Pharmacol; 2020 Jan; 866():172784. PubMed ID: 31730760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Efficacy and Safety Assessment of Artemisinin-Chemotherapeutic Agent Conjugates for Ovarian Cancer.
    Li X; Zhou Y; Liu Y; Zhang X; Chen T; Chen K; Ba Q; Li J; Liu H; Wang H
    EBioMedicine; 2016 Dec; 14():44-54. PubMed ID: 27939426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death.
    Abdullah MI; Abed MN; Khanim F; Richardson A
    Sci Rep; 2019 Jul; 9(1):9632. PubMed ID: 31270377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug repositioning in cancer: The current situation in Japan.
    Masuda T; Tsuruda Y; Matsumoto Y; Uchida H; Nakayama KI; Mimori K
    Cancer Sci; 2020 Apr; 111(4):1039-1046. PubMed ID: 31957175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enterolactone has stronger effects than enterodiol on ovarian cancer.
    Liu H; Liu J; Wang S; Zeng Z; Li T; Liu Y; Mastriani E; Li QH; Bao HX; Zhou YJ; Wang X; Hu S; Gao S; Qi Y; Shen Z; Wang H; Yu M; Gao T; Johnston RN; Liu SL
    J Ovarian Res; 2017 Jul; 10(1):49. PubMed ID: 28738876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?
    Kobayashi Y; Banno K; Kunitomi H; Nagai S; Takahashi T; Anko M; Iijima M; Takeda T; Matoba Y; Nakamura K; Tsuji K; Tominaga E; Aoki D
    Eur J Cancer Prev; 2019 Nov; 28(6):562-567. PubMed ID: 30418231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs.
    Bhattarai D; Singh S; Jang Y; Hyeon Han S; Lee K; Choi Y
    Curr Top Med Chem; 2016; 16(19):2156-68. PubMed ID: 26881715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systems biology based drug repositioning for development of cancer therapy.
    Turanli B; Altay O; Borén J; Turkez H; Nielsen J; Uhlen M; Arga KY; Mardinoglu A
    Semin Cancer Biol; 2021 Jan; 68():47-58. PubMed ID: 31568815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer.
    Banno K; Iida M; Yanokura M; Irie H; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    ScientificWorldJournal; 2015; 2015():341362. PubMed ID: 25734181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms.
    Chuffa LGA; Reiter RJ; Lupi LA
    Carcinogenesis; 2017 Oct; 38(10):945-952. PubMed ID: 28575150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based drug repositioning: Potential and limits.
    Adasme MF; Parisi D; Sveshnikova A; Schroeder M
    Semin Cancer Biol; 2021 Jan; 68():192-198. PubMed ID: 32032699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repositioning approved drugs for the treatment of problematic cancers using a screening approach.
    Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
    PLoS One; 2017; 12(2):e0171052. PubMed ID: 28166232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Old drugs, new uses: Drug repurposing in hematological malignancies.
    Kale VP; Habib H; Chitren R; Patel M; Pramanik KC; Jonnalagadda SC; Challagundla K; Pandey MK
    Semin Cancer Biol; 2021 Jan; 68():242-248. PubMed ID: 32151704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Silico Oncology Drug Repositioning and Polypharmacology.
    Cheng F
    Methods Mol Biol; 2019; 1878():243-261. PubMed ID: 30378081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.
    Saburi A; Kahrizi MS; Naghsh N; Etemadi H; İlhan A; Adili A; Ghoreishizadeh S; Tamjidifar R; Akbari M; Ercan G
    J Ovarian Res; 2022 Jul; 15(1):81. PubMed ID: 35799305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Repurposing in the Development of Anticancer Agents.
    Olgen S; Kotra LP
    Curr Med Chem; 2019; 26(28):5410-5427. PubMed ID: 30009698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics.
    Modesitt SC; Jazaeri AA
    Expert Opin Pharmacother; 2007 Oct; 8(14):2293-305. PubMed ID: 17927484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
    Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
    Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.